CLINICAL TRIALS PROFILE FOR TROGLITAZONE
✉ Email this page to a colleague
All Clinical Trials for troglitazone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003058 ↗ | Troglitazone in Treating Patients With Liposarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-06-01 | Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype. |
| NCT00003058 ↗ | Troglitazone in Treating Patients With Liposarcoma | Completed | Dana-Farber Cancer Institute | Phase 2 | 1997-06-01 | Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype. |
| NCT00116545 ↗ | TART - Troglitazone Atherosclerosis Regression Trial | Completed | Parke-Davis | Phase 2/Phase 3 | 1997-01-01 | The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients. |
| NCT00242177 ↗ | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 1 | 2003-10-01 | The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients. |
| NCT00242177 ↗ | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Completed | University of Illinois at Chicago | Phase 1 | 2003-10-01 | The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients. |
| NCT00290394 ↗ | Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients | Completed | Baskent University | Phase 4 | 2004-03-01 | The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects. |
| NCT00412126 ↗ | Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI | Completed | Heart and Stroke Foundation of Canada | N/A | 2002-07-01 | Coronary artery disease is a process that results in "hardening of the arteries". When the arteries that supply blood and oxygen to your heart muscle become clogged or narrowed, a heart attack may result, or you may feel chest discomfort (angina) - sometimes even while resting. One approach to treating this condition is a balloon procedure known as coronary angioplasty. The major limitation of coronary angioplasty is renarrowing of the artery (restenosis) in the first six months following the procedure requiring either repeat angioplasty or referral for bypass surgery. Patients with diabetes have always been identified as having higher rates of restenosis and poor outcomes following angioplasty, despite some important scientific advances. We think that the level of blood sugar control at the time of angioplasty and in the following months may be related to the extent of restenosis. We expect that a reduction in blood sugar with insulin may, in turn, reduce the restenosis process and improve your long-term outcome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for troglitazone
Condition Name
Clinical Trial Locations for troglitazone
Trials by Country
Clinical Trial Progress for troglitazone
Clinical Trial Phase
Clinical Trial Sponsors for troglitazone
Sponsor Name
